Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/monitoring-for-hepatotoxicity-what-is-the-predictive-value-of-liver-XkVJUIuEcy
References (31)
-
P. Lindblom, I. Rafter, C. Copley, U. Andersson, J. Hedberg, A. Berg, Anders Samuelsson, H. Hellmold, I. Cotgreave, B. Glinghammar (2007)
Isoforms of alanine aminotransferases in human tissues and serum--differential tissue expression using novel antibodies.Archives of biochemistry and biophysics, 466 1
-
R. Andrade, M. Lucena, M. Fernández, G. Pelaez, K. Pachkoria, E. García-Ruiz, B. García-Muñoz, R. González‐Grande, Á. Pizarro, J. Duran, M. Jiménez, L. Rodrigo, M. Romero‐Gomez, J. Navarro, R. Planas, Joan Costa, A. Borràs, Aina Soler, J. Salmerón, R. Martín-Vivaldi (2005)
Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.Gastroenterology, 129 2
-
(2007)
Draft guidance for industry -
C. Nolan, S. Goldberg, S. Buskin (1999)
Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.JAMA, 281 11
-
J. Ozer, Marcia Ratner, Martin Shaw, W. Bailey, S. Schomaker (2008)
The current state of serum biomarkers of hepatotoxicity.Toxicology, 245 3
-
J. Awapara, B. Seale (1952)
Distribution of transaminases in rat organs.The Journal of biological chemistry, 194 2
-
L. Seeff (1980)
Guidelines for detection of hepatotoxicity due to drugs and chemicalsGastroenterology, 79
-
Mary Willy, Zili Li (2004)
What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labelingPharmacoepidemiology and Drug Safety, 13
-
P. Watkins, H. Zimmerman, M. Knapp, S. Gracon, K. Lewis (1994)
Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease.JAMA, 271 13
-
A. Sniderman (2004)
Is there value in liver function test and creatine phosphokinase monitoring with statin use?The American journal of cardiology, 94 9A
-
P. Adams, Michael Arthur, T. Boyer, L. DeLeve, A. Bisceglie, M. Hall, T. Levin, D. Provenzale, Leonard Seeff (2004)
Screening in liver disease: Report of an AASLD clinical workshopHepatology, 39
-
Paul Watkins, Randall Whitcomb (1998)
Hepatic dysfunction associated with troglitazone.The New England journal of medicine, 338 13
-
R. Swick, P. Barnstein, J. Stange (1965)
THE METABOLISM OF MITOCHONDRIAL PROTEINS. I. DISTRIBUTION AND CHARACTERIZATION OF THE ISOZYMES OF ALANINE AMINOTRANSFERASE IN RAT LIVER.The Journal of biological chemistry, 240
-
L. McNeill, Myra Allen, C. Estrada, P. Cook (2003)
Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity.Chest, 123 1
-
J. Lewis (2006)
‘Hy's law,’ the ‘Rezulin Rule,’ and other predictors of severe drug‐induced hepatotoxicity: putting risk‐benefit into perspectivePharmacoepidemiology and Drug Safety, 15
-
(2008)
Liver Test Elevations in Patients on Placebo -
D. Graham, L. Green, J. Senior, P. Nourjah (2003)
Troglitazone-induced liver failure: a case study.The American journal of medicine, 114 4
-
K. Clay, J. Hanson, Scott Pope, R. Rissmiller, P. Purdum, P. Banks (2006)
Brief Communication: Severe Hepatotoxicity of Telithromycin: Three Case Reports and Literature ReviewAnnals of Internal Medicine, 144
-
(2008)
Was It the Drug, or a Disease -
P. Watkins, Paul Seligman, J. Pears, M. Avigan, J. Senior (2008)
Using controlled clinical trials to learn more about acute drug‐induced liver injuryHepatology, 48
-
(2008)
Lessons from Isoniazid: Would It Be Approved Today? (see slide 12) -
M. Beghetti, M. Hoeper, D. Kiely, J. Carlsen, B. Schwierin, Eleanor Segal, M. Humbert (2008)
Safety Experience With Bosentan in 146 Children 2–11 Years Old With Pulmonary Arterial Hypertension: Results from the European Postmarketing Surveillance ProgramPediatric Research, 64
-
H. Zimmerman (1978)
Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver -
A. Karmen (1955)
A note on the spectrometric assay of glutamic-oxalacetic transaminase in human blood serum.The Journal of clinical investigation, 34 1
-
D. Kopanoff, D. Snider, G. Caras (1978)
Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.The American review of respiratory disease, 117 6
-
A. Karmen, F. Wróblewski, J. Ladue (1955)
Transaminase activity in human blood.The Journal of clinical investigation, 34 1
-
(2006)
Liver Adaptation to Xenobiotic Injury -
H. Zimmerman (2015)
The Spectrum of HepatotoxicityPerspectives in Biology and Medicine, 12
-
E. Björnsson, R. Olsson (2005)
Outcome and prognostic markers in severe drug‐induced liver diseaseHepatology, 42
-
(2007)
Draft guidance for industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation -
(2001)
Hepatotoxicity Through the Years: Impact on the FDA
- Publisher
- Wiley
- Copyright
- © 2009 American Society for Clinical Pharmacology and Therapeutics
- ISSN
- 0009-9236
- eISSN
- 1532-6535
- DOI
- 10.1038/clpt.2008.262
- Publisher site
- See Article on Publisher Site
Abstract
Drug‐induced liver injury (DILI) is a major reason drugs fail during development or are withdrawn from the market.1 The ability to predict, detect, and avoid DILI through appropriate patient selection and effective monitoring has proved to be an elusive goal. Many approved drugs have labeling recommendations for serum enzyme monitoring intended to detect and prevent hepatotoxicity, but such monitoring is often seen as inconvenient, uncomfortable, costly, and inefficient by both patients and doctors, and thus monitoring recommendations are poorly followed, if at all. This review considers whether monitoring works to prevent DILI, whether monitoring recommendations are derived from data or opinions, and whether any better alternatives exist.
Journal
Clinical Pharmacology & Therapeutics – Wiley
Published: Mar 1, 2009